Study guide
11.3 Multiple Myeloma & Plasma Cell Dyscrasias
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
11.3 Multiple Myeloma & Plasma Cell Dyscrasias
Key Takeaways Explain This Topic AI
Multiple Myeloma is diagnosed by >=10% clonal bone marrow plasma cells (or biopsy-proven plasmacytoma) plus CRAB features (Hypercalcemia, Renal failure, Anemia, Bone lesions) or SLiM high-risk biomarkers (>=60% plasma cells, involved/uninvolved FLC ratio >=100, >1 focal MRI bone lesion).
Frontline quadruplet therapy with Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (D-VRd per GRIFFIN/PERSEUS) is the standard of care for transplant-eligible myeloma, followed by high-dose melphalan conditioned ASCT and lenalidomide maintenance; transplant-ineligible patients receive Daratumumab + Lenalidomide + Dexamethasone (D-Rd per MAIA).
Immunomodulatory drugs (IMiDs: lenalidomide, pomalidomide) mandate strict REMS participation, risk-stratified thromboprophylaxis (aspirin for low-risk; therapeutic LMWH or DOAC for high-risk combinations), and dose adjustments for renal clearance.
Proteasome inhibitors demand signature toxicity monitoring: bortezomib requires subcutaneous administration and mandatory acyclovir/valacyclovir prophylaxis to prevent Herpes Zoster reactivation; carfilzomib requires blood pressure control and cardiovascular monitoring for heart failure and ischemic events.
Relapsed/refractory myeloma has been revolutionized by BCMA-directed CAR T-cell therapies (ciltacabtagene autoleucel, idecabtagene vicleucel), BCMA bispecific T-cell engagers (teclistamab, elranatamab with IVIG support for hypogammaglobulinemia), and the GPRC5D bispecific talquetamab (requiring management of oral dysgeusia, dysphagia, skin desquamation, and nail dystrophy).
Last updated: August 2026
11.3 Multiple Myeloma & Plasma Cell Dyscrasias
Multiple Myeloma is a clonal plasma cell neoplasm originating in the bone marrow that secretes monoclonal immunoglobulins ( M-protein / paraprotein ) or free light chains (kappa or lambda). The unregulated expansion of these malignant plasma cells disrupts normal hematopoiesis, stimulates osteoclast-mediated bone destruction, causes tubular nephropathy, and impairs humoral immunity.
Over the past two decades, the treatment paradigm for myeloma has transformed dramatically from melphalan-prednisone alkylator therapy into multi-target combinations of Immunomodulatory Drugs (IMiDs) , Proteasome Inhibitors (PIs) , Anti-CD38 Monoclonal Antibodies , BCMA- and GPRC5D-directed Bispecific Antibodies , and Autologous CAR T-Cell Therapies .
1. Diagnostic Criteria, Staging & Risk Stratification
According to the International Myeloma Working Group ( IMWG ), diagnosis requires >= 10% clonal bone marrow plasma cells (or biopsy-proven plasmacytoma) PLUS at least one of the classic CRAB features or SLiM biomarkers of malignancy : +-----------------------------------------------------------------------------+
- | IMWG MULTIPLE MYELOMA DIAGNOSTIC CRITERIA |
- | |
- | [CLASSIC CRAB FEATURES (End-Organ Damage)] |
- | - **C** (Hypercalcemia): Serum Calcium > 11 mg/dL (or > 1 mg/dL above ULN)|
- | - **R** (Renal Insufficiency): Serum Creatinine > 2 mg/dL or CrCl < 40 mL/|
- | - **A** (Anemia): Hemoglobin < 10 g/dL (or > 2 g/dL below lower limit) |
- | - **B** (Bone Lesions): >= 1 osteolytic lesion on skeletal radiography, |
- | CT, or PET-CT |
- | |
- | [SLiM BIOMARKERS OF MALIGNANCY (>= 80% 2-Year Progression Risk)] |
- | - **S** (Sixty Percent): **>= 60% clonal bone marrow plasma cells** |
- | - **Li** (Light Chain Ratio): Involved-to-uninvolved serum **Free Light |
- | Chain (FLC) ratio >= 100** (involved >= 100) |
- | - **M** (MRI Focal Lesions): **> 1 focal lesion (>= 5 mm)** on MRI scans |
- +-----------------------------------------------------------------------------+
- Revised International Staging System (R-ISS & R2-ISS)
Prognosis is governed by tumor burden (serum beta-2 microglobulin and albumin), serum lactate dehydrogenase (LDH), and high-risk chromosomal abnormalities detected by interphase FISH: +-----------------------------------------------------------------------------+
- | R-ISS STAGING & HIGH-RISK CYTOGENETICS |
- | |
- | [HIGH-RISK CYTOGENETICS BY FISH] |
- | - **del(17p) / TP53 deletion** (associated with aggressive biology / EMD) |
- | - **t(4;14)(p16;q32)** (FGFR3 / MMSET deregulation) |
- | - **t(14;16)(q32;q23)** (c-MAF deregulation) |
- | - **t(14;20)(q32;q11)** (MAFB deregulation) |
- | - **1q21 Gain / Amplification (+1q21 / amp1q21)** |
- | |
- | [R-ISS STAGES] |
- | - **Stage I:** ISS Stage I (Serum beta-2 microglobulin < 3.5 mg/L AND |
- | Albumin >= 3.5 g/dL) + Standard-risk FISH + Normal Serum LDH |
- | - **Stage III:** ISS Stage III (Serum beta-2 microglobulin >= 5.5 mg/L) |
- | AND EITHER High-risk FISH OR Elevated Serum LDH |
- | - **Stage II:** All other combinations not fitting Stage I or III |
- +-----------------------------------------------------------------------------+
2. Frontline Induction Paradigms: Quadruplets vs Triplets +-----------------------------------------------------------------------------+
- | FRONTLINE MULTIPLE MYELOMA ALGORITHM |
- | |
- | NEWLY DIAGNOSED ACTIVE MULTIPLE MYELOMA |
- | | |
- | Assess ASCT Eligibility (Age, Frailty, Organ Fn) |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v v |
- | [TRANSPLANT-ELIGIBLE] [TRANSPLANT-INELIGIBLE]|
- | - **D-VRd Quadruplet Induction** (4-6 cycles) - **D-Rd Triplet** |
- | * Daratumumab SC 1800 mg weekly/Q3W * Daratumumab SC |
- | * Bortezomib 1.3 mg/m2 SC D1,4,8,11 * Lenalidomide 25 mg |
- | * Lenalidomide 25 mg PO D1-14 Q21D * Dexamethasone 40 mg|
- | * Dexamethasone 20-40 mg weekly - (MAIA Trial: median |
- | * (GRIFFIN & PERSEUS Trials: superior uMRD) PFS > 61.9 months!) |
- | | - Alternative (Frail): |
- | v * VRd-Lite |
- | [HIGH-DOSE MELPHALAN (200 mg/m2) + ASCT] |
- | | |
- | v |
- | [POST-ASCT MAINTENANCE THERAPY] |
- | - Standard Risk: **Lenalidomide 10-15 mg PO daily (D1-21 Q28D or cont.)**|
- | (CALGB 10010 meta-analysis: +2.5 year overall survival benefit) |
- | - High Risk: **Bortezomib Q2W** OR **Daratumumab + Lenalidomide** |
- +-----------------------------------------------------------------------------+
3. Core Myeloma Drug Classes: Mechanisms, Toxicities & Pharmacist Interventions +-----------------------------------------------------------------------------+
- | CORE MYELOMA PHARMACOTHERAPY MASTER REFERENCE |
- +-----------------------------------------------------------------------------+
- | 1. IMMUNOMODULATORY DRUGS (IMiDs: Lenalidomide, Pomalidomide, Thalidomide) |
- | - Mechanism: Bind **CEREBLON (CRBN)**, part of the CRL4-CRBN E3 ubiquitin|
- | ligase complex -> triggers proteasomal degradation of Ikaros (IKZF1) |
- | and Aiolos (IKZF3) -> downregulates IRF4 and MYC, activates T/NK cells.|
- | - **Teratogenicity:** Strict REMS program mandate (Lenalidomide REMS, |
- | Pomalyst REMS); mandatory 2 forms of contraception, 28-day supply limit|
- | - **Venous Thromboembolism (VTE):** High risk when combined with steroids|
- | - **Renal Dosing (Lenalidomide is renally cleared):** |
- | * CrCl 30-50 mL/min: 10 mg PO daily |
- | * CrCl < 30 mL/min: 15 mg PO Q48H or 5 mg daily |
- | * Hemodialysis: 5 mg PO daily administered post-dialysis |
- |-----------------------------------------------------------------------------|
- | 2. PROTEASOME INHIBITORS (PIs: Bortezomib, Carfilzomib, Ixazomib) |
- | - Mechanism: Inhibit 20S core of 26S proteasome -> unfolded protein |
- | response, ER stress, apoptosis; downregulates NF-kappaB. |
- | - **Bortezomib (Velcade):** Reversible boronate inhibitor. |
- | * Toxicity: Peripheral neuropathy (PN: 10% SC vs 40% IV). Use SC route!|
- | * Mandatory Prophylaxis: **Acyclovir 400 mg PO BID** or Valacyclovir |
- | 500 mg daily for **Herpes Zoster (VZV) reactivation** prevention. |
- | - **Carfilzomib (Kyprolis):** Irreversible epoxyketone inhibitor. |
- | * Toxicity: **Cardiotoxicity / Heart Failure (8-10%)**, Hypertension |
- | (20-25%), Pulmonary Hypertension, Dyspnea, Microangiopathy. |
- | * Pharmacist Mandate: Monitor BP; avoid excessive IV pre-hydration. |
- | - **Ixazomib (Ninlaro):** Oral boronate PI. Take on empty stomach (1h b/ |
- | 2h after food); GI toxicity, thrombocytopenia, rash. |
- |-----------------------------------------------------------------------------|
- | 3. ANTI-CD38 MONOCLONAL ANTIBODIES (Daratumumab, Isatuximab) |
- | - Mechanism: Target CD38 surface glycoprotein; CDC, ADCC, ADCP, apoptosis|
- | - **Daratumumab (Darzalex / Darzalex Faspro [1800 mg SC + Hyaluronidase])|
- | - **BLOOD BANK INTERFERENCE (CRITICAL BOARD PEARL):** |
- | * Binds CD38 on reagent red blood cells, causing a **FALSE-POSITIVE |
- | INDIRECT COOMBS TEST (Indirect Antiglobulin Test [IAT])** for up to |
- | 6 months post-treatment! |
- | * PHARMACY MANDATE: Obtain **Baseline Type & Screen with Extended Red |
- | Blood Cell Phenotyping/Genotyping PRIOR TO FIRST DOSE** of anti-CD38.|
- | * Inform blood bank to treat reagent RBCs with **Dithiothreitol (DTT)**|
- | to denature surface CD38 (note: DTT destroys Kell [K] antigens). |
- +-----------------------------------------------------------------------------+
IMiD-Associated VTE Risk Assessment & Pharmacotherapy +-----------------------------------------------------------------------------+
- | IMWG / ASCO THROMBOPROPHYLAXIS ALGORITHM |
- | |
- | PATIENT RECEIVING IMiD (Lenalidomide / Pomalidomide) + CORTICOSTEROID |
- | | |
- | Calculate VTE Risk Factors (SAVED or IMPEDE Score) |
- | - Risk Factors: Prior VTE, BMI >= 30, High-Dose Dexamethasone (>=480 mg/m)|
- | Concurrent Doxorubicin, Immobilization, Hyperviscosity, Renal failure |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v (0 to 1 Individual Risk Factor) v (>=2 Factors) |
- | [LOW VTE RISK] [HIGH VTE RISK] |
- | - **Aspirin 81 mg to 325 mg PO daily** - **LMWH (Enoxaparin |
- | 40 mg SC daily)** OR |
- | - **DOAC (Apixaban |
- | 2.5 mg PO BID or |
- | Rivaroxaban 10 mg)** |
- | - **Warfarin (INR 2-3)**
- +-----------------------------------------------------------------------------+
- 4. Relapsed/Refractory Myeloma: Biologics, Bispecifics & CAR T-Cell Therapy
For patients progressing on frontline PIs, IMiDs, and anti-CD38 antibodies ( triple-class refractory disease ), recent breakthroughs have transformed outcomes: +-----------------------------------------------------------------------------+
- | NOVEL TARGETED PARADIGMS IN RELAPSED / REFRACTORY MM |
- +-----------------------------------------------------------------------------+
- | 1. BCMA-DIRECTED CAR T-CELL THERAPIES |
- | - **Ciltacabtagene autoleucel (Cilta-cel; Carvykti):** CARTITUDE-4 trial |
- | (Binds 2 distinct BCMA epitopes). Unprecedented ORR >95%, deep CRs. |
- | * Signature Toxicities: CRS, ICANS, Delayed Movement / Parkinsonism. |
- | - **Idecabtagene vicleucel (Ide-cel; Abecma):** KarMMa-3 trial. |
- |-----------------------------------------------------------------------------|
- | 2. BCMA-DIRECTED BISPECIFIC ANTIBODIES (BiTEs) |
- | - **Teclistamab (Tecvayli):** Binds BCMA on myeloma + CD3 on T cells. |
- | * Subcutaneous step-up dosing: 0.06 mg/kg -> 0.3 mg/kg -> 1.5 mg/kg. |
- | - **Elranatamab (Elrexfio):** Subcutaneous step-up dosing to 76 mg QW. |
- | - PHARMACY MANDATE FOR BCMA BISPECIFICS: |
- | * **Severe Hypogammaglobulinemia (IgG < 400 mg/dL):** Mandatory monthly|
- | **Intravenous Immunoglobulin (IVIG 0.4-0.5 g/kg)** replacement to |
- | prevent catastrophic opportunistic infections. |
- | * PJP prophylaxis (TMP-SMX) and anti-herpetic prophylaxis (Acyclovir). |
- |-----------------------------------------------------------------------------|
- | 3. GPRC5D-DIRECTED BISPECIFIC ANTIBODY |
- | - **Talquetamab (Talvey):** Binds **G Protein-Coupled Receptor Family C |
- | Group 5 Member D (GPRC5D)** on plasma cells + CD3 on T cells. |
- | - MonumenTAL-1 trial: Highly effective post-BCMA therapy failure! |
- | - SIGNATURE ON-TARGET / OFF-TUMOR TOXICITIES: |
- | * **Oral Toxicity (Dysgeusia / Ageusia / Dry Mouth in 70-80%):** Lead |
- | to weight loss; manage with saliva stimulants, ice chips, zinc. |
- | * **Skin & Nail Toxicities (Palmar-plantar desquamation, Nail |
- | Dystrophy / Onycholysis in 50-60%):** Treat with high-potency topical|
- | corticosteroids and ammonium lactate / urea creams. |
- |-----------------------------------------------------------------------------|
- | 4. NUCLEAR EXPORT INHIBITOR: SELINEXOR (Xpovio) |
- | - Mechanism: Selective Inhibitor of Nuclear Export (SINE); inhibits |
- | **Exportin-1 (XPO1)**, forcing nuclear retention of p53, IkappaB, Rb. |
- | - Dosing: 100 mg PO weekly (+ Bortezomib/Dex per BOSTON trial). |
- | - PHARMACY MANDATE: **Severe Nausea, Anorexia & Hyponatremia** |
- | * Mandatory Prophylaxis: **5-HT3 antagonist (Ondansetron)** PLUS |
- | **Olanzapine 2.5 to 5 mg PO daily** at bedtime. |
- |-----------------------------------------------------------------------------|
- | 5. BCL-2 INHIBITOR IN t(11;14) MYELOMA: VENETOCLAX |
- | - Translocation t(11;14)(q13;q32) creates high BCL-2 to MCL-1 ratio. |
- | - Venetoclax 400-800 mg PO daily combined with dexamethasone +/- PI |
- | yields remarkable >80% response rates specifically in t(11;14) disease!|
- +-----------------------------------------------------------------------------+
5. Supportive Care in Myeloma: Bone Health, Renal Care & AL Amyloidosis +-----------------------------------------------------------------------------+
- | SUPPORTIVE PHARMACOTHERAPY & AL AMYLOIDOSIS PROTOCOLS |
- | |
- | 1. BONE-MODIFYING AGENTS (BMAs) IN MULTIPLE MYELOMA |
- | - Indication: All active myeloma patients requiring therapy, regardless|
- | of whether lytic bone lesions are visible on baseline imaging. |
- | - **Zoledronic Acid (4 mg IV Q3-4W):** Reduce dose for baseline renal |
- | impairment (CrCl 50-60: 3.5 mg; 40-49: 3.3 mg; 30-39: 3.0 mg). Avoid|
- | if CrCl < 30 mL/min. |
- | - **Denosumab (120 mg SC Q4W per Raje et al. Lancet Oncol 2018):** |
- | * Preferred agent in renal insufficiency (CrCl < 30 mL/min or ESRD). |
- | * Does NOT require renal dose adjustment. |
- | * CRITICAL PEARL: Severe **Hypocalcemia Risk** and **Rebound Fractures|
- | upon Abrupt Discontinuation** (consolidate with bisphosphonate). |
- | - Osteonecrosis of the Jaw (ONJ) Prevention: Mandatory baseline dental |
- | exam; hold BMAs prior to invasive dental procedures. |
- | |
- | 2. AL AMYLOIDOSIS (LIGHT CHAIN AMYLOIDOSIS) |
- | - Pathophysiology: Clonal plasma cells produce misfolded light chains |
- | that deposit as amyloid fibrils in heart (restrictive cardiomyopathy)|
- | kidneys (nephrotic syndrome), liver, and autonomic nervous system. |
- | - Frontline Standard (ANDROMEDA Trial: Kastritis et al. NEJM 2021): |
- | **Daratumumab SC + CyBorD (Cyclophosphamide + Bortezomib + Dex)** |
- | * Achieves rapid, deep hematologic complete response and organ |
- | reversal (cardiac and renal response). |
- +-----------------------------------------------------------------------------+
- Master Multiple Myeloma Pharmacotherapy Summary
Clinical Setting Standard Regimens Key Toxicities & Boxed Warnings Essential Pharmacist Action Points
Frontline Transplant-Eligible D-VRd -> ASCT -> Lenalidomide maintenance Neuropathy (Bortezomib), VTE/cytopenias (Lenalidomide), Coombs interference (Dara) Baseline extended red blood cell phenotyping; Acyclovir for VZV; Enoxaparin/Aspirin for VTE; SC bortezomib.
Frontline Transplant-Ineligible D-Rd (MAIA) or VRd-Lite Fatigue, Diarrhea, Pneumonia, Neutropenia, VTE Monthly IVIG if IgG <400 with infections; renal dose adjustment for Lenalidomide; VTE prophylaxis.
Relapsed (Triple-Class Exposed) Teclistamab / Elranatamab (BCMA BiTE) CRS, ICANS, Severe Neutropenia, Opportunistic Sepsis Step-up inpatient dosing; Dexamethasone premedication; monthly IVIG replacement; PJP/VZV prophylaxis.
Relapsed (GPRC5D-Targeted) Talquetamab (GPRC5D BiTE) Dysgeusia/Ageusia, Dysphagia, Weight Loss, Palmar-plantar desquamation, Nail loss Counsel on saliva stimulants, mouth ice chips, zinc; topical urea/steroid creams for skin/nails.
Relapsed (t(11;14) Translocation) Venetoclax + Dexamethasone Nausea, Diarrhea, Neutropenia, Sepsis Biomarker testing for t(11;14) by FISH; prophylactic antimicrobials; monitor CBC.
Bone Disease Management Zoledronic Acid OR Denosumab Renal tubular necrosis (Zoledronic), Severe Hypocalcemia (Denosumab), ONJ Calcium + Vitamin D co-prescription; dental clearance; use Denosumab if CrCl < 30 mL/min.
AL Amyloidosis Dara-CyBorD (ANDROMEDA) Fluid retention, Arrhythmias, Neuropathy, Hypotension Monitor NT-proBNP and troponin; avoid rapid IV hydration due to amyloid cardiomyopathy.